364621-46-5

TFCP2L1-IN-1 is a specific small molecule targeting TFCP2L1’s active domain with anti-cancer activity. TFCP2L1-IN-1 synergizes with Sorafenib (HY-10201) to induce Apoptosis and reduces cell proliferation, invasion, metastasis, clonal formation and sphere-forming capacity in hepatocellular carcinoma cells[1].

[1] Qiu D, et al. TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma. Oncogenesis. 2024 Sep 12;13(1):33. DOI:10.1038/s41389-024-00534-1